The role of hematopoietic stem cell transplantation in chronic myeloid leukemia
read more
Citations
Management of CML-blast crisis
Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).
Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment.
Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study.
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
References
Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure.
A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation
An overview of HLA typing for hematopoietic stem cell transplantation.
A Chance of Cure for Every Patient with Chronic Myeloid Leukemia
Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy.
Related Papers (5)
Current role of stem cell transplantation in chronic myeloid leukaemia.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
Frequently Asked Questions (9)
Q2. What has shifted the community from major University centers towards decentralized medical practice?
The ease of drug administration has as well shifted the patient community from major University centers towards decentralized medical practice.
Q3. What is the role of HSCT in the treatment of CML?
Ease of application and improved response to modern drug therapy has almost halted HSCT for multiple myeloma and limited HSCT to selected patients [13, 14].
Q4. What was the powerful tool in CML?
Relapse risk was highest after T cell depletion in CML compared to other diseases, in contrast, donor lymphocyte infusion (DLI) proved to be the most powerful tool in CML.
Q5. What is the current recommendation of the ELN?
Current recommendations of professional organizations such as the ELN should consider integration of a quality management system into the treatment algorithm.
Q6. What is the role of the patient’s advocacy groups in the decision to end a transplant?
In order to arrive at such a policy, patients and patient’s advocacy groups need to be informed, cooperation has to be established between the local medical community and the transplant centers, professional organizations have to adapt recommendations within a quality management system and to collect and analyze the appropriate data.
Q7. What is the general consensus on HSCT?
The general consensus appears that allogeneic HSCT offers a reasonable outcome even in accelerated phase or blast crisis [52–57].
Q8. How much is the probability of survival after an allogeneic HSCT?
Hence,the general statement that the probability of survival after an allogeneic HSCT for CML at 5 years is 60 % is of limited value; it might range frommore than 90% to less than 5%.
Q9. What is the way to treat HSCT?
In case of early failure, HSCT could be considered rapidly for those with minimal transplant risks; drug treatment changed for those without this option.